Hüppa põhisisu juurde
Raamatukoi
Tõde ja õigus

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

Shabir Ahmad Ganai · Springer Verlag, Singapore · 2020

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity.

The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity..

Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

Saadavus
183,50 €

Uus kasutamata raamat

Raamat tellimisel — tarneaeg umbes 10 päeva (27.11.2026)Tellimuse täitmise aeg on umbkaudne ja sõltub nädalapäevast, millal tellimus tehakse. Reeglina ei kulu üle kahe nädala.

Tarne ja kättesaamine

Detailid

ISBN
9789811581786
Aasta
2020
Keel
inglise
Köide
Kõva kaas
Lehekülgi
258
Teema
Meditsiin › Prekliinilised alusteadused — Pre-clinical medicine: basic sciences
Kaal
542 g